Supernus PharmaceuticalsSUPN +1.53%87 EBITDA Margin % is 9.72% as of Mar. 2026, which is 64% below its 10-year median of 26.93. GuruFocus rates SUPN with a GF Score™ of 87/100 and a GF Value™ of $40.55 (Modestly Overvalued). Among 955 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 65.86% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Supernus Pharmaceuticals EBITDA Margin % Related Terms
Supernus Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SUPN vs BCRX, PBH, ANIP: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (SUPN) has a EBITDA Margin % of 9.72% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Supernus Pharmaceuticals and its competitors. This is 64% below median its historical median of 26.93. Over the past decade, Supernus Pharmaceuticals' EBITDA Margin % has ranged from 5.79 to 45.03. According to the industry distribution chart, Supernus Pharmaceuticals ranks #629 out of 955 companies in the Drug Manufacturers industry, placing it in the top 65.9%.
Is Supernus Pharmaceuticals' EBITDA Margin % too high?
Supernus Pharmaceuticals' current EBITDA Margin % of 9.72% is 64% below median its 10-year median of 26.93. Over the past 10 years, this metric has ranged from a low of 5.79 to a high of 45.03. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Supernus Pharmaceuticals' value of 9.72% is 21.5% below this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #629 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' EBITDA Margin % compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #629 out of 955 companies for EBITDA Margin %. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Supernus Pharmaceuticals' value of 9.72% is 21.5% below this benchmark. Historically, Supernus Pharmaceuticals' own EBITDA Margin % has ranged from 5.79 to 45.03 over the past decade. While the company's 10-year median is 26.93 vs. the industry median of 12.39, Supernus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current EBITDA Margin % of 9.72% is 21.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current EBITDA Margin % is 9.72%, which is 64% below median its own 10-year median of 26.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (SUPN) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.55, compared to a current price of $45.13 — trading 11.3% above its estimated fair value. The current EBITDA Margin % is 9.72%, which is 64% below median its 10-year median of 26.93 and 21.5% below the Drug Manufacturers industry median of 12.39. Supernus Pharmaceuticals' overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Supernus Pharmaceuticals (SUPN), the current EBITDA Margin % is 9.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (SUPN) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $45.13 is trading 11.3% above its estimated GF Value™ of $40.55.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for SUPN:
EBITDA Margin %: 9.72% (64% below median its 10-year median of 26.93)
GF Value™: $40.55 vs. price of $45.13 (11.3% above fair value)
Industry Position: 21.5% below the Drug Manufacturers median (#629 of 955)
No single metric tells the full story. See the SUPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score
Get the complete analysis for SUPN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUPN has been successfully added to your 
